Arbutus Biopharma Corp (ABUS) Stock: What the Analysts are Saying


The stock has a 36-month beta value of 1.96. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”

The public float for ABUS is 146.65M, and at present, short sellers hold a 3.66% of that float. On July 11, 2024, the average trading volume of ABUS was 984.57K shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

ABUS) stock’s latest price update

Arbutus Biopharma Corp (NASDAQ: ABUS)’s stock price has soared by 0.29 in relation to previous closing price of 3.40. Nevertheless, the company has seen a gain of 8.95% in its stock price over the last five trading days. reported 2024-07-05 that Arbutus Biopharma’s three-pronged strategy targets cHBV by suppressing HBV DNA, reducing viral antigens, and boosting immune response. Imdusiran (AB-729) shows promise in Phase 2 trials, potentially leading to a functional cure for chronic hepatitis B. ABUS is engaged in significant IP litigation with Moderna, Pfizer, and BioNTech over LNP technology used in mRNA vaccines.

ABUS’s Market Performance

Arbutus Biopharma Corp (ABUS) has experienced a 8.95% rise in stock performance for the past week, with a 6.56% rise in the past month, and a 13.48% rise in the past quarter. The volatility ratio for the week is 4.00%, and the volatility levels for the past 30 days are at 3.43% for ABUS. The simple moving average for the past 20 days is 9.21% for ABUS’s stock, with a 35.49% simple moving average for the past 200 days.

Analysts’ Opinion of ABUS

Many brokerage firms have already submitted their reports for ABUS stocks, with Jefferies repeating the rating for ABUS by listing it as a “Buy.” The predicted price for ABUS in the upcoming period, according to Jefferies is $5 based on the research report published on February 02, 2022 of the previous year 2022.

Jefferies, on the other hand, stated in their research note that they expect to see ABUS reach a price target of $5. The rating they have provided for ABUS stocks is “Hold” according to the report published on February 25th, 2021.

H.C. Wainwright gave a rating of “Buy” to ABUS, setting the target price at $10 in the report published on December 17th of the previous year.

ABUS Trading at 10.66% from the 50-Day Moving Average

After a stumble in the market that brought ABUS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.32% of loss for the given period.

Volatility was left at 3.43%, however, over the last 30 days, the volatility rate increased by 4.00%, as shares surge +8.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +24.91% upper at present.

During the last 5 trading sessions, ABUS rose by +8.95%, which changed the moving average for the period of 200-days by +71.36% in comparison to the 20-day moving average, which settled at $3.14. In addition, Arbutus Biopharma Corp saw 36.40% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ABUS starting from McElhaugh Michael J., who sale 10,164 shares at the price of $2.31 back on Feb 02 ’24. After this action, McElhaugh Michael J. now owns 1,504,793 shares of Arbutus Biopharma Corp, valued at $23,504 using the latest closing price.

Sofia Michael J., the Chief Scientific Officer of Arbutus Biopharma Corp, sale 9,982 shares at $2.31 during a trade that took place back on Feb 02 ’24, which means that Sofia Michael J. is holding 1,485,121 shares at $23,083 based on the most recent closing price.

Stock Fundamentals for ABUS

Current profitability levels for the company are sitting at:

  • -6.13 for the present operating margin
  • 0.89 for the gross margin

The net margin for Arbutus Biopharma Corp stands at -5.73. The total capital return value is set at -0.61. Equity return is now at value -57.54, with -43.56 for asset returns.

Based on Arbutus Biopharma Corp (ABUS), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -11.14. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -373.92.

Currently, EBITDA for the company is -76.63 million with net debt to EBITDA at 0.45. When we switch over and look at the enterprise to sales, we see a ratio of 46.86. The receivables turnover for the company is 4.74for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.69.


To sum up, Arbutus Biopharma Corp (ABUS) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Most Popular

Related Posts